Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments.
Few issues are as controversial in non-small cell lung cancer as the management of patients with stage IIIA-N2 non-small cell lung cancer. This manuscript reviews the reasons and the biases inherent to this controversy and discusses the different treatment approaches with emphasis on survival as evidenced by meta-analyses and large randomised clinical trials. Prospects on novel treatment modalities and future research opportunities are presented.
van Meerbeeck
Jan P
JP
Department of Respiratory Medicine & Thoracic Oncology, University Hospital, Ghent, Belgium. jan.vanmeerbeeck@ugent.be
Surmont
Veerle F M
VF
D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy / Q000639:trends; D004358:Drug Therapy / Q000639:trends; D017408:Guidelines as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D015201:Meta-Analysis as Topic; D009367:Neoplasm Staging; D011878:Radiotherapy / Q000639:trends; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis